ORICOric Pharmaceuticals, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$142M
- 0.0% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$27M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$79M | −$92M | −$111M | −$143M | −$143M | 0.1% |
| Net income | −$79M | −$89M | −$101M | −$128M | −$129M | 1.3% |
| Operating cash flow | −$60M | −$75M | −$86M | −$113M | −$111M | 1.5% |
| Capex | $939K | $2M | $849K | $1M | $712K | 40% |
| Stock-based comp | $13M | $14M | $15M | $20M | $25M | 24% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $465K · 6
- Net
- −$465K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $6M | $6M | 89 | — |
| FY2024 | $5M | $4M | 88 | — |